



HAEMONETICS®

Haemonetics CEO Completes Open Market Share Purchase

August 8, 2016

BRAINTREE, Mass., Aug. 8, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that Christopher Simon, President and CEO, has acquired 60,000 shares of the Company's common stock at an average price per share of \$35.00. The acquisition of these shares was by open market purchases taking place during the last three business days.



HAEMONETICS®

Mr. Simon joined the Company as Chief Executive Officer effective May 16, 2016. Under the terms of his compensation agreement, the Company will match up to \$2 million of his share purchases with an equal number of relative performance-based share units. The vesting and value of the share units are conditional upon Mr. Simon's continued employment with the Company and the achievement of three-year performance conditions established by the Company's compensation committee.

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for our customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at <http://www.haemonetics.com>.

INVESTOR CONTACT:

Gerry Gould, VP-Investor Relations
(781) 356-9402
gerry.gould@haemonetics.com

MEDIA CONTACT:

Sandra Jesse, Executive VP
(781) 356-9253
sandra.jesse@haemonetics.com

Logo - <http://photos.prnewswire.com/prnh/20160405/3515681LOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/haemonetics-ceo-completes-open-market-share-purchase-300310555.html>

SOURCE Haemonetics Corporation